Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914033 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 | |
| SCHEMBL20954451 | 0.83 | CYP4F2 (0.60) | MAOBMAOASMN1; SMN2NR4A2CYP4F2 | |
| SCHEMBL29060106 | 0.81 | BCHE (0.57) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 | |
| SCHEMBL11268094 | 0.79 | NOX1 (0.74) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 | |
| SCHEMBL24349140 | 0.79 | SIRT2 (0.46) | CYP1A2CYP2C19LTA4HNOX1MAOB | |
| SCHEMBL339813 | 0.78 | LMNA (0.82) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 | |
| SCHEMBL3324625 | 0.77 | LTA4H (0.52) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 | |
| SCHEMBL5021020 | 0.77 | CALM1 (0.48) | CYP2C19LMNALTA4HMAPTRAB9A | |
| SCHEMBL9451327 | 0.77 | ALDH1A1 (0.69) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 | |
| SCHEMBL7786204 | 0.76 | MAOB (0.53) | CYP1A2CYP2C19LMNAPTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153934-B | Polyester dispersants, synthesis and uses thereof | 雪佛龙奥伦耐有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| EP-1355876-B1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RES INST ROYAL (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-7183319-B2 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY | 2007-02-27 | — | — | US | disclosed |
| US-7183319-B2 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY | 2007-02-27 | — | — | US | disclosed |
| US-6916949-B2 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20040087813-A1 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2004-05-06 | — | — | US | disclosed |
| EP-1355876-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002060862-A1 | METHODS OF CHEMICAL SYNTHESIS OF PHENOLIC NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | CYP1A2 2380/4885CYP2C19 2115/4885LMNA 1399/4885 |
| US-20040087813-A1 | Methods of chemical systhesis of phenolic nitrogen mustard prodrugs | GGH, GLUL, GSS | CYP1A2 792/4885CYP2C19 1437/4885LMNA 1533/4885 |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | PCNA, WEE1, UNG | CYP1A2 3815/4885CYP2C19 4577/4885LMNA 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.